Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for difficult-to-treat cancers, particularly within the oncology and immuno-oncology sectors. The company’s strategy centers on leveraging tumor biology and immune system interactions to create targeted therapeutics designed to improve efficacy while reducing off-target toxicity. Pyxis Oncology does not currently have commercialized products and does not generate product revenue, with operations funded primarily through equity financing and public capital markets.
The company’s core programs are built around antibody-drug conjugates (ADCs) and monoclonal antibodies targeting validated and emerging cancer-associated pathways. Pyxis Oncology aims to differentiate itself through selective target biology, rational payload design, and precision-based development. The company was founded in 2019 and became publicly traded in 2021, positioning itself as a research-driven oncology developer focused on advancing candidates through early and mid-stage clinical development.
Business Operations
Pyxis Oncology operates as a single-reporting-segment company focused on oncology drug discovery and clinical development. Its primary business activities include target validation, preclinical research, clinical trial execution, and regulatory development for its pipeline of antibody-based therapeutics. The company’s lead programs include PYX-201, an ADC targeting Extradomain-B fibronectin (EDB-FN), and PYX-106, a monoclonal antibody program designed to modulate immune-related signaling pathways relevant to solid tumors.
Operations are primarily U.S.-based, with clinical trials conducted through third-party contract research organizations and clinical sites. Pyxis Oncology relies heavily on external manufacturing partners for drug substance and drug product production and maintains intellectual property portfolios related to antibody engineering, linker-payload technologies, and target-specific applications. The company does not currently report material revenue from collaborations or licensing agreements.
Strategic Position & Investments
Strategically, Pyxis Oncology is focused on advancing its clinical pipeline through proof-of-concept studies in solid tumors with high unmet medical need. Growth initiatives are centered on progressing PYX-201 through clinical development, expanding indications where EDB-FN expression is prevalent, and optimizing dosing strategies to support later-stage trials. The company has publicly stated its intent to selectively expand its pipeline through internal research rather than large-scale acquisitions.
Pyxis Oncology has not reported any completed acquisitions of other companies and does not maintain a diversified investment portfolio. Its assets primarily consist of internally developed drug candidates and associated intellectual property. Emerging areas of focus include next-generation ADC design and immune-targeting biologics, with ongoing evaluation of additional oncology targets supported by translational research data.
Geographic Footprint
Pyxis Oncology is headquartered in the United States, with its principal executive offices located in Boston, Massachusetts, a major global biotechnology hub. The company’s operational footprint is concentrated in North America, where corporate management, research oversight, and development strategy are based.
Internationally, Pyxis Oncology’s presence is primarily indirect, achieved through clinical trial sites and third-party service providers supporting global development activities. While the company does not maintain significant physical operations outside the U.S., its clinical programs are designed to support future regulatory submissions in multiple regions, including Europe and other international oncology markets, subject to clinical outcomes.
Leadership & Governance
Pyxis Oncology is led by an executive team with experience across oncology drug development, clinical research, and biotechnology operations. The leadership team emphasizes a science-driven culture focused on disciplined clinical execution and strategic capital allocation to advance high-impact oncology programs.
Key executives include:
- Lara S. Sullivan, M.D. – President and Chief Executive Officer
- Jeffrey J. Bean – Chief Financial Officer
- John M. Flavin, Ph.D. – Chief Scientific Officer
- Holly A. Manning – Chief Business Officer
The company is governed by a board of directors comprising industry executives, scientific leaders, and financial professionals, providing oversight on corporate strategy, risk management, and shareholder alignment.